Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Basket Study of Larotrectinib in NTRK Fusion-Positive Tumors (EU CTIS 20289)
2022-502667-38-00Phase 2Completed
- Sponsor
- Bayer
- Start
- Jan 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 14
01
Overview
Phase 2, open-label, single-arm trial of larotrectinib in Nonhematologic neoplasms and Central nervous system tumor harboring NTRK gene fusion, sponsored by Bayer. Started Jan 2024; status: completed.
02
Drugs
larotrectinib
03
Conditions
Nonhematologic neoplasmsCentral nervous system tumor harboring NTRK gene fusion
Beyond the preview
Go deeper on 2022-502667-38-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502667-38-00.